Mark S. Milner, MD is a board-certified ophthalmologist and a fellowship-trained corneal surgeon. He received his bachelor of science degree from Union College and his doctor of medicine degree from the State University of New York Health Science Center, Syracuse, NY. Dr. Milner interned in internal medicine at Robert Wood Johnson University Hospital, New Brunswick, NJ, and completed his residency in ophthalmology at the New York Eye and Ear Infirmary. His fellowship in cornea, external disease, and uveitis was completed at the prestigious Francis I. Proctor Foundation at the University of California, San Francisco.

Dr. Milner is an Associate Clinical Professor at Yale University Medical School, Department of Ophthalmology. He was both a co-founder and co-medical Director of Precision LASIK Group, Cheshire, CT. He previously held the positions of Director of the Cornea Clinic at The Veterans Administration Medical Center in West Haven, CT and the Medical Director of Education for Sunrise Technologies. Dr. Milner was also a Co-Chief Medical Officer of Eyevance Pharmaceuticals, and currently holds a position on the Scientific Advisory Board for Okyo Pharma. He now is Director of Cornea at Goldman Eye in Palm Beach Gardens, Florida.

Dr. Milner is actively involved in research. He has been a principle investigator for several studies for FDA approval including, but not limited to, 32 spot Laser Thermal Keratoplasty (LTK) with Sunrise Holium Laser, the effects of diquafasol tetrasodium ophthalmic solution on subjects with dry eye syndrome, the safety & efficacy of Azithromycin ophthalmic solution in the treatment of blepharitis, and the safety & efficacy of two different topical ophthalmic solutions, EBI-005 and KPI-121 for the treatment of dry eye disease. He has authored various publications, including a 44-page peer-reviewed article in Current Opinion in Ophthalmology (January 2017) detailing his innovative algorithm and approach to the diagnosis and treatment of dry eye disease, and has been interviewed by several magazines, newspaper, radio and television programs about his refractive and corneal expertise. He was featured in an article as the only ophthalmologist between NY and Boston to perform the IMT (Implantable Miniature Telescope) surgery for patients with advanced macular degeneration and blindness. He was awarded with the Yale Department of Ophthalmology Teaching Award for “Excellence in Teaching” in 1998 and was voted a “Top Doctor” in 2009, 2010, 2011, 2012, 2013, 2014, and 2015 in Connecticut Magazine by his peers. In 2016, he was selected on the list of Ocular Surgery News (OSN) Premier Surgeon 300 as one of the top 300 premier surgeons and leading innovators in the US in the field of refractive cataract surgery. In 2022 and 2023, Dr Milner was featured in Newsweek as one of “America’s Best Eye Doctors.” Dr. Milner specializes in cornea, external diseases, refractive surgery, and uveitis, with a focused interest in dry eye disease and dysfunctional tear syndrome. He has built a large dry eye practice and has lectured throughout the world teaching other physicians about dysfunctional tear syndrome and his innovative approach, algorithm, and treatments. Dr. Milner was one of the first physicians in the northeast to perform the newly approved Corneal Collagen Cross-linking (CXL) procedure, with the only FDA approved Glaukos/Avedro device.

Dr. Milner is a Fellow of the American College of Surgeons and is a member of the American Board of Ophthalmology, the American Medical Association, the International Society of Refractive Surgery, the American Society of Cataract and Refractive Surgery, and is a founding member, President Elect, and board member of the CEDARS/ASPENS Society (Cornea External Diseases and Refractive Surgery).